scorecardresearchSyncom Formulations India Share Price Live NSE, BSE, Today - Syncom Formulations

Syncom Formulations India

BSE: 524470 | NSE: SYNCOMF | ISIN: INE312C01025 | SECTOR: Biotechnology & Drugs

8.50 0.06 (0.71%)

27 Sep 2023, 09:59 (IST)
  • Open

    8.44
  • High

    8.73
  • Low

    8.42
  • Prev Close

    8.44
  • P/E

    -
  • Median P/E

    -
  • P/B

    -
  • Median P/B

    -
  • Market Cap

    7.99B
  • Volume

    624.05K
  • Vol. (20 day Avg.)

    0
  • PEG

    -
  • Div.Yield

    -
  • Bid

    8.51
  • Ask

    -

Company Description

  • Biotechnology & Drugs
  • BSE

    524470
  • NSE

    SYNCOMF
  • ISIN

    INE312C01025

Syncom Formulations (India) Limited is an India-based company that is engaged in the pharmaceutical business. The Company is engaged in the manufacturing and dealing in pharmaceutical drugs and formulations, and trading of commodities. It is also engaged in the renting of properties. It manufactures and markets a range of pharmaceutical formulations in various dosage forms, such as tablets, capsules, liquids orals, liquid vials and ampoule injections and dry powder injections, ophthalmic preparations, dry syrups and suspensions, ointments, creams, gel, ORS and jelly. The Company's domestic division product categories include Cratus Life Care, Cratus Evolve and Cratus Right Nutrition. Its products include Ciprofloxacin Tablets USP 250 mg, Ciprofloxacin Tablets USP 500 mg, Ciprofloxacin Tablets USP 750 mg, Cefazolin For Injection USP 1 gm, Cefotaxime For Injection USP 1 gm, Ceftriaxone for Injection USP 500 mg, Cefuroxime For Injection USP 750 mg and Gentamicin Injection BP 40 mg.

Company Officers

  • Kedarmal Bankda

    Executive Chairman of the Board
  • Ankit Bankda

    Chief Financial Officer
  • Vaishali Agrawal

    Compliance Officer, Company Secretary
  • Vijay Bankda

    Managing Director, Executive Director
  • Rinki Bankda

    Whole-Time Director